



26th February 2021

Dear Honourable Minister of Health,

Last week, we released a letter that the AstraZeneca AZD1222 vaccine has been granted Emergency Use Listing by WHO, and is thus authorised for delivery under the COVAX Facility. Following up on the 29th January letter regarding your indicative allocation, we are now pleased to share with you the final allocation for the first round of AZD1222 vaccine doses to be provided to your economy in the coming months.

AstraZeneca

Honduras is allocated **424,800 doses of the AZD1222 vaccine** through May 2021.

For more information regarding allocation and next steps, we invite you to consult the key details in Annex A attached to this letter. Please note that AMC participants will soon receive a Decision Letter formally and legally approving the above allocation of doses and related funding from the COVAX Facility.

Pfizer/BioNTech

For participants who expressed interest in BNT162b2 Q2 doses, given the specificity of the vaccine and the additional requirements placed on countries by the manufacturer in order to access the vaccine, projected Q2 doses from Pfizer will be included through a separate allocation round in March. Based on early learnings from the first wave countries, the COVAX Facility will soon reach out with more information regarding Q2 doses.

Procurement of AZD1222 vaccine and next steps

This first allocation round allows for the procurement process to be planned and implemented for phased deliveries. UNICEF and PAHO RF will be placing purchase orders, provided participants have completed all prerequisite steps noted below.

If not already completed, we therefore once again urge you to ensure that i) you have signed an indemnity agreement with AstraZeneca, ii) you have executed and provided documentation of national regulatory approval or proof of recognition or reliance on another type of regulatory approval, as well as an import license provision for relevant vaccine products to your respective procurement agency (PAHO Revolving Fund for the Region of Americas and UNICEF Supply Division for all other regions), iii) you ensure that your NDVP has been uploaded to the [COVID-19 Partners Platform](#) and validated by your Ministry of Health.

Please note that due the high number of participants covered under this allocation round, the capacity of the supplier and the freight forwarders will be under considerable pressure. When planning for the receipt of the vaccines and program implementation, in addition to the preparedness requirements above, please also factor in supply lead time for (1) purchase order processing and approval, (2) final supply packing and release, (3) logistical preparedness and planning, and (4) shipping prioritization and lead times (which vary based on airline capacity availability, location of the participant, etc.).

Thank you for your continued engagement with the COVAX Facility. Please note that in order to maintain the COVAX Facility's commitment to transparency, we may publish on our website information related to participant status of pre-requisites, in order to provide clarity on the likely earliest deliveries for the first round of allocation. Following this letter, we will also make this allocation information publicly available soon after the weekend. If you require any further clarifications, do not hesitate to contact your focal point or Gavi Senior Country Manager.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Aurélia Nguyen', with a long horizontal flourish extending to the right.

Aurélia Nguyen
Managing Director
Office of the COVAX Facility